Top 5 Stocks to Buy Now
→ Trump's gold order: the announcement they won't put on the front page (From Reagan Gold Group) (Ad)tc pixel
NASDAQ:HELP

Cybin Q1 2025 Earnings Report

Cybin logo
$6.52 +0.50 (+8.31%)
As of 01:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Cybin EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Cybin Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cybin Announcement Details

Quarter
Q1 2025
Date
8/8/2024
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Cybin Earnings Headlines

Cybin (NASDAQ:HELP) Trading 18.3% Higher - What's Next?
June 26 at 2:21 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30861607
Helus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug Pipeline
June 25 at 11:31 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/helus-pharma-raises-us50-million-to-advance-late-stage-mental-health-drug-pipeline?utm_source=marketbeat.com&utm_medium=referral
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
June 26 at 1:00 AM  |  Reagan Gold Group (Ad)
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
June 25 at 9:27 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/25/3317639/0/en/helus-pharma-announces-closing-of-us-50-million-underwritten-offering.html
Helus Pharma™ Announces US$50 Million Underwritten Offering
June 24 at 6:01 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316649/0/en/helus-pharma-announces-us-50-million-underwritten-offering.html
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment Progress
June 24 at 6:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316644/0/en/helus-pharma-provides-update-on-approach-phase-3-trial-enrollment-progress.html
See More Cybin Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cybin? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cybin and other key companies, straight to your email.

About Cybin

Cybin (NASDAQ:HELP) is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations. Cybin’s work spans preclinical research through clinical trials, with an emphasis on optimizing pharmacology, dosing and delivery to improve safety, tolerability and the patient experience. Its R&D approach combines chemistry, formulation science and clinical development to advance candidate therapies toward regulatory review.

Cybin’s therapeutic efforts target a range of mental health indications that commonly include mood and anxiety disorders and substance-use disorders. The company pursues both internal development programs and collaborative relationships with academic and industry partners to support clinical development, regulatory strategy and potential commercialization pathways.

As a publicly traded biotechnology company, Cybin’s operations encompass research and development activities across multiple jurisdictions, with clinical programs conducted in regions where regulatory frameworks permit investigational studies of psychedelic-assisted treatments. The company positions itself to expand therapeutic options for patients and to contribute to the evolving scientific and clinical understanding of psychedelic-derived medicines.

View Cybin Profile
Earnings Tools